Tablets "Femoston ^® " are applied by Konti at the following indications:

• replacement hormonal therapy (RHT) for elimination of the symptoms caused by deficiency of estrogen at women during the menopauzny period not earlier than in 12 months from the moment of the last periods;
• prevention of osteoporosis at women during the post-menopausal period at high risk of changes ("Femoston ^® Konti" should be applied to patients only in case of intolerance or existence of contraindications to use of other medicines to prevention of osteoporosis).

Structure

One tablet contains (active ingredients) of oestradiol of the gemigidrat, micronized that is equivalent to oestradiol of 1 mg; the didrogesteron micronized 5 mg.

Excipients: lactose, monohydrate; gipromelloz (HPMC 2910), starch corn, silicon dioxide colloidal waterless, magnesium stearate.

Film covering: the mixed film covering of Orange I (polyethyleneglycol 400, a gipromelloz (HPMC 2910), ferrous oxide yellow (E172), ferrous oxide red (E172), the titan dioxide (E 171)).

Contraindication

• cancer of mammary glands diagnosed in the past, available or suspected;
• established or suspected estrogenchuvstvitelny tumors (for example endometrial cancer);
• vaginal bleedings of not clear genesis;
• not treated hyperplasia of endometrium;
• an active venous thrombembolia in the anamnesis (deep vein thrombosis, a thrombembolia of pulmonary arteries);
• existence of trombofilichesky frustration (for example deficiency of a protein With, a protein of S or antithrombin);
• acute or recently postponed thromboembolic disease of arteries (for example stenocardia, a myocardial infarction);
• an acute disease of a liver or a disease of a liver in the anamnesis at which indicators of function of a liver were not normalized;
• porphyria;
• known hypersensitivity to active ingredients or to any of medicine excipients.

"Femoston ^® Konti" to apply

orally daily according to the continuous combined mode as it is described below.

to Accept

on one tablet daily during each 28-day cycle. Each blister is intended for treatment within 28 days. After that it is necessary to begin a new cycle immediately. Such cycles of treatment which follow one after another are continuous.

For treatment of deficiency of estrogen at women during the post-menopausal period as an initial and maintenance dose should accept the lowest effective dose, and period duration treatment has to be as it is possible well. The continuous combined treatment can be begun with medicine "Femoston ^® Konti" depending on time which passed from the beginning of a menopause and weight of symptoms. Women at whom the menopause came naturally can begin medicament treatment in 12 months after the last periods. Women at whom the menopause was caused by surgical intervention can begin treatment immediately. The dose should be selected individually depending on the clinical answer.

At the women who are not performing replacement hormonal therapy or at the women passing from the continuous combined replacement hormonal therapy, treatment it is possible to begin in any convenient day. At women who pass from cyclic or continuous consecutive replacement hormonal therapy the treatment should be begun from the next day after the termination of the previous cycle at once.

If reception of a dose is missed by

, it should be accepted as soon as possible. If passed more, than 12 hours, treatment it is recommended to continue on reception of the following tablet, without taking the passed pill. In such cases of the passed tablet the probability of breakthrough bleeding or bloody discharges can increase.

can take the Drug irrespective of meal.

Pregnant

Drug is not shown to

Feature of application

for application during pregnancy. If pregnancy occurred during medicament treatment "Femoston ^® Konti", intake of medicine should be stopped immediately.

Drug is not shown to

for application during feeding by a breast.

"Femoston ^® Konti" is not shown by

for application to women of reproductive age.

Children

by

for application for children.

Drivers

Drug does not influence or has insignificant impact on ability to drive the car or to work with mechanisms.

Overdose

As oestradiol, and didrogesteron are substances with hypotoxicity. At overdose there can be such symptoms as nausea, vomiting, sensitivity of mammary glands, dizziness, an abdominal pain, drowsiness/fatigue and bleeding of cancellation. It is improbable that at overdose any specific or symptomatic treatment will be required. Information described above belongs also to overdose cases at children.

Side effects

Most frequent side reactions at patients to whom performed therapy by oestradiol / didrogesteronom at conduct of clinical trials were a headache, an abdominal pain, pain/sensitivity of mammary glands and a back pain.

to Store

in original packing at a temperature not above 30 °C, out of children's reach.

Expiration date - 3 years.